Clinical results from a Phase I/IIa trial with the chitosan based adjuvant ViscoGel

Guro GafvelinGuro Gafvelin, Viscogel joined us last year at the World Vaccine Congress Europe to present on ‘Clinical results from a Phase I/IIa trial with the chitosan based adjuvant ViscoGel’

Download this presentation now to find out more about:

  • ViscoGel® – a viscoelastic hydrogel based on chitosan
  • Unique advantages of ViscoGel as adjuvant
  • Model vaccine for Proof-of-concept studies of ViscoGel as adjuvant
  • Pre-clinical evaluation: ViscoGel enhances the antibody response to Act-HIB
  • ViscoGel enhances the cellular response and promotes a mixed cytokine profile in response to Act-HIB

…And much more!

Get your copy here!

If you are interested in finding out more about vaccine supply, then join us at the 15th Annual World Vaccine Congress Europe.

Vaccines-EU-2014-728x96-600x74

 

Leave a Reply

Your email address will not be published. Required fields are marked *